

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Tian et al.

Docket No.: 11134-059-99
RECEIVED
CENTRAL FAX CENTER

Serial No: 09/837,992

Group Art Unit: 1652

Filed: April 18, 2001

Examiner: Christian L. Fronda

For: SITOSTEROLEMIA SUSCEPTIBILITY
GENE(SSG): COMPOSITIONS AND
METHODS OF USE

APR 08 2009

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450STATEMENT UNDER 37 C.F.R. 3.73(b)

Amgen Inc. (hereinafter "Amgen"), a corporation of the State of Delaware having a place of business at One Amgen Center Drive, Thousand Oaks, California, 91320, is the assignee of the entire right, title, and interest in the above-identified U.S. patent application. A chain of title from the inventors of the above-identified application to Amgen Inc. is shown below.

1. From inventors Hui Tian, Joshua Schultz and Bei Shan
To: Tularik, Inc. the assignment recorded September 28, 2001, in the USPTO at Reel 012222, Frame 0512
2. From Tularik, Inc. To: Arrow Acquisition, LLC the assignment recorded June 7, 2005, in the USPTO at Reel 016309, Frame 0003.
3. From Arrow Acquisition, LLC To: Amgen SF, LLC the assignment recorded June 7, 2005, in the USPTO at Reel 016309, Frame 0812.
4. From Amgen SF, LLC To: Amgen Inc. the assignment recorded October 18, 2005, in the USPTO at Reel 016871, Frame 0736.

The undersigned, whose title is supplied below, is empowered to sign this statement on behalf of Amgen.

REVOCATION OR PREVIOUS POWER OF ATTORNEY AND
NEW POWER OF ATTORNEY BY ASSIGNEE

Amgen hereby revokes all previous powers of attorney given in the above-identified application and hereby appoints the registered practitioners at Customer Number 21069 to prosecute this application, to make and to transact all business in the Patent and Trademark Office connected therewith.

REQUEST FOR CHANGE OF CORRESPONDENCE ADDRESS

Please send all future correspondence and direct telephone calls to Customer Number 20583.

Respectfully submitted,

Date May 22 2006

By: Stuart L. Watt
Stuart L. Watt
Vice President, Law
AMGEN INC.

CAUD: 524843.1

AMGEN REC'D. 100 011 1 US